NASDAQ:AMEH

Apollo Medical Competitors

$91.51
+2.59 (+2.91 %)
(As of 08/4/2021 02:03 PM ET)
Add
Compare
Today's Range
$87.90
$94.52
50-Day Range
$34.79
$112.84
52-Week Range
$16.21
$114.55
Volume22,291 shs
Average Volume679,270 shs
Market Capitalization$5.03 billion
P/E Ratio75.63
Dividend YieldN/A
Beta0.58

Apollo Medical (NASDAQ:AMEH) Vs. BAH, G, EXPO, FCN, ICFI, and MEG

Should you be buying AMEH stock or one of its competitors? Companies in the industry of "management consulting services" are considered alternatives and competitors to Apollo Medical, including Booz Allen Hamilton (BAH), Genpact (G), Exponent (EXPO), FTI Consulting (FCN), ICF International (ICFI), and Montrose Environmental Group (MEG).

Booz Allen Hamilton (NYSE:BAH) and Apollo Medical (NASDAQ:AMEH) are both business services companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Institutional & Insider Ownership

88.8% of Booz Allen Hamilton shares are held by institutional investors. Comparatively, 11.5% of Apollo Medical shares are held by institutional investors. 1.9% of Booz Allen Hamilton shares are held by insiders. Comparatively, 12.3% of Apollo Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Booz Allen Hamilton has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Apollo Medical has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Profitability

This table compares Booz Allen Hamilton and Apollo Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Booz Allen Hamilton7.24%53.87%10.07%
Apollo Medical6.73%16.81%5.68%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Booz Allen Hamilton and Apollo Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Booz Allen Hamilton03602.67
Apollo Medical00103.00

Booz Allen Hamilton presently has a consensus price target of $90.8571, indicating a potential upside of 9.78%. Apollo Medical has a consensus price target of $75.00, indicating a potential downside of 17.75%. Given Booz Allen Hamilton's higher probable upside, research analysts clearly believe Booz Allen Hamilton is more favorable than Apollo Medical.

Earnings & Valuation

This table compares Booz Allen Hamilton and Apollo Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Booz Allen Hamilton$7.86 billion1.43$608.96 million$3.9021.31
Apollo Medical$687.18 million7.32$37.87 million$1.0190.60

Booz Allen Hamilton has higher revenue and earnings than Apollo Medical. Booz Allen Hamilton is trading at a lower price-to-earnings ratio than Apollo Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Booz Allen Hamilton beats Apollo Medical on 10 of the 14 factors compared between the two stocks.

Genpact (NYSE:G) and Apollo Medical (NASDAQ:AMEH) are both mid-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Profitability

This table compares Genpact and Apollo Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genpact8.41%20.88%7.59%
Apollo Medical6.73%16.81%5.68%

Institutional & Insider Ownership

98.0% of Genpact shares are held by institutional investors. Comparatively, 11.5% of Apollo Medical shares are held by institutional investors. 2.4% of Genpact shares are held by insiders. Comparatively, 12.3% of Apollo Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Genpact and Apollo Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genpact$3.71 billion2.50$308.28 million$1.8526.79
Apollo Medical$687.18 million7.32$37.87 million$1.0190.60

Genpact has higher revenue and earnings than Apollo Medical. Genpact is trading at a lower price-to-earnings ratio than Apollo Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Genpact has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Apollo Medical has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genpact and Apollo Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genpact01302.75
Apollo Medical00103.00

Genpact presently has a consensus price target of $50.50, indicating a potential upside of 2.35%. Apollo Medical has a consensus price target of $75.00, indicating a potential downside of 17.75%. Given Genpact's higher probable upside, research analysts clearly believe Genpact is more favorable than Apollo Medical.

Summary

Genpact beats Apollo Medical on 10 of the 14 factors compared between the two stocks.

Apollo Medical (NASDAQ:AMEH) and Exponent (NASDAQ:EXPO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Apollo Medical and Exponent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apollo Medical6.73%16.81%5.68%
Exponent21.94%26.17%16.65%

Institutional & Insider Ownership

11.5% of Apollo Medical shares are held by institutional investors. Comparatively, 89.4% of Exponent shares are held by institutional investors. 12.3% of Apollo Medical shares are held by company insiders. Comparatively, 1.8% of Exponent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Apollo Medical and Exponent's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollo Medical$687.18 million7.32$37.87 million$1.0190.60
Exponent$399.90 million14.35$82.55 million$1.5571.05

Exponent has lower revenue, but higher earnings than Apollo Medical. Exponent is trading at a lower price-to-earnings ratio than Apollo Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Apollo Medical has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Exponent has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Apollo Medical and Exponent, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apollo Medical00103.00
Exponent01202.67

Apollo Medical currently has a consensus price target of $75.00, indicating a potential downside of 17.75%. Exponent has a consensus price target of $118.00, indicating a potential upside of 7.31%. Given Exponent's higher possible upside, analysts plainly believe Exponent is more favorable than Apollo Medical.

Summary

Exponent beats Apollo Medical on 9 of the 14 factors compared between the two stocks.

Apollo Medical (NASDAQ:AMEH) and FTI Consulting (NYSE:FCN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Apollo Medical and FTI Consulting's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apollo Medical6.73%16.81%5.68%
FTI Consulting8.81%16.75%8.58%

Institutional & Insider Ownership

11.5% of Apollo Medical shares are held by institutional investors. 12.3% of Apollo Medical shares are held by company insiders. Comparatively, 3.3% of FTI Consulting shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Apollo Medical and FTI Consulting's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollo Medical$687.18 million7.32$37.87 million$1.0190.60
FTI Consulting$2.46 billion2.01$210.68 million$5.9924.13

FTI Consulting has higher revenue and earnings than Apollo Medical. FTI Consulting is trading at a lower price-to-earnings ratio than Apollo Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Apollo Medical has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, FTI Consulting has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Apollo Medical and FTI Consulting, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apollo Medical00103.00
FTI Consulting00103.00

Apollo Medical currently has a consensus price target of $75.00, indicating a potential downside of 17.75%. FTI Consulting has a consensus price target of $170.00, indicating a potential upside of 17.72%. Given FTI Consulting's higher possible upside, analysts plainly believe FTI Consulting is more favorable than Apollo Medical.

Apollo Medical (NASDAQ:AMEH) and ICF International (NASDAQ:ICFI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Apollo Medical and ICF International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apollo Medical6.73%16.81%5.68%
ICF International4.11%11.66%5.24%

Institutional & Insider Ownership

11.5% of Apollo Medical shares are held by institutional investors. Comparatively, 90.8% of ICF International shares are held by institutional investors. 12.3% of Apollo Medical shares are held by company insiders. Comparatively, 4.1% of ICF International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Apollo Medical and ICF International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollo Medical$687.18 million7.32$37.87 million$1.0190.60
ICF International$1.51 billion1.11$54.96 million$4.1721.24

ICF International has higher revenue and earnings than Apollo Medical. ICF International is trading at a lower price-to-earnings ratio than Apollo Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Apollo Medical has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, ICF International has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Apollo Medical and ICF International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apollo Medical00103.00
ICF International00403.00

Apollo Medical currently has a consensus price target of $75.00, indicating a potential downside of 17.75%. ICF International has a consensus price target of $110.1667, indicating a potential upside of 24.29%. Given ICF International's higher possible upside, analysts plainly believe ICF International is more favorable than Apollo Medical.

Summary

ICF International beats Apollo Medical on 7 of the 13 factors compared between the two stocks.

Apollo Medical (NASDAQ:AMEH) and Montrose Environmental Group (NYSE:MEG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Apollo Medical and Montrose Environmental Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apollo Medical6.73%16.81%5.68%
Montrose Environmental Group-7.06%17.90%2.68%

Institutional & Insider Ownership

11.5% of Apollo Medical shares are held by institutional investors. Comparatively, 68.4% of Montrose Environmental Group shares are held by institutional investors. 12.3% of Apollo Medical shares are held by company insiders. Comparatively, 16.9% of Montrose Environmental Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Apollo Medical and Montrose Environmental Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollo Medical$687.18 million7.32$37.87 million$1.0190.60
Montrose Environmental Group$328.24 million4.05$-57,950,000.00($4.69)-10.87

Apollo Medical has higher revenue and earnings than Montrose Environmental Group. Montrose Environmental Group is trading at a lower price-to-earnings ratio than Apollo Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Apollo Medical and Montrose Environmental Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apollo Medical00103.00
Montrose Environmental Group06602.50

Apollo Medical currently has a consensus price target of $75.00, indicating a potential downside of 17.75%. Montrose Environmental Group has a consensus price target of $35.7727, indicating a potential downside of 29.94%. Given Apollo Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Apollo Medical is more favorable than Montrose Environmental Group.

Summary

Apollo Medical beats Montrose Environmental Group on 9 of the 13 factors compared between the two stocks.


Apollo Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Booz Allen Hamilton logo
BAH
Booz Allen Hamilton
2.7$83.10+0.4%$11.25 billion$7.86 billion20.22Earnings Report
Dividend Announcement
Analyst Report
Analyst Revision
Genpact logo
G
Genpact
2.5$49.57+0.1%$9.29 billion$3.71 billion30.98Upcoming Earnings
Dividend Announcement
Exponent logo
EXPO
Exponent
2.2$110.13+0.5%$5.74 billion$399.90 million60.85Earnings Report
Dividend Announcement
Analyst Report
Analyst Revision
FTI Consulting logo
FCN
FTI Consulting
1.9$144.52+0.5%$4.95 billion$2.46 billion22.13Earnings Report
Insider Selling
Analyst Revision
ICF International logo
ICFI
ICF International
2.6$88.55+0.2%$1.67 billion$1.51 billion26.91Earnings Report
News Coverage
Montrose Environmental Group logo
MEG
Montrose Environmental Group
2.1$51.00+2.7%$1.33 billion$328.24 million-16.29Upcoming Earnings
News Coverage
The RMR Group logo
RMR
The RMR Group
2.2$37.83+2.4%$1.19 billion$589.51 million23.64Upcoming Earnings
Analyst Downgrade
News Coverage
Huron Consulting Group logo
HURN
Huron Consulting Group
2.6$46.97+0.7%$1.05 billion$871.01 million44.73Earnings Report
Analyst Revision
The Hackett Group logo
HCKT
The Hackett Group
2.5$17.69+0.7%$533 million$239.48 million98.28Upcoming Earnings
News Coverage
Atlas Technical Consultants logo
ATCX
Atlas Technical Consultants
2.0$12.95+6.9%$466.46 million$468.22 million-10.28Short Interest ↓
GBOX
GreenBox POS
0.3$10.13+3.9%$428.80 million$8.52 million0.00Positive News
TWND
Tailwind Acquisition
0.3$9.94+0.5%$415.29 millionN/A0.00Positive News
BlackRock Capital Investment logo
BKCC
BlackRock Capital Investment
1.6$3.87+0.5%$286.96 million$67.12 million-8.60Upcoming Earnings
Information Services Group logo
III
Information Services Group
2.7$5.73+3.8%$275.10 million$249.13 million38.20Upcoming Earnings
BWMN
Bowman Consulting Group
2.1$13.04+1.5%$144.22 millionN/A0.00Upcoming Earnings
Analyst Upgrade
News Coverage
Positive News
Gap Up
LIVK
LIV Capital Acquisition
0.2$10.04+0.0%$101.71 millionN/A0.00Short Interest ↑
Avalon GloboCare logo
AVCO
Avalon GloboCare
1.2$0.98+4.6%$82.31 million$1.38 million-6.50Upcoming Earnings
News Coverage
Negative News
ATIF
ATIF
0.8$0.85+9.4%$39.95 million$690,000.000.00Short Interest ↓
Lightbridge logo
LTBR
Lightbridge
0.9$5.98+3.7%$39.47 millionN/A-1.89Upcoming Earnings
Wilhelmina International logo
WHLM
Wilhelmina International
1.5$5.07+20.5%$26.16 million$41.60 million-507.00Upcoming Earnings
Insider Buying
News Coverage
Gap Down
HUSN
Hudson Capital
0.0$3.11+0.0%$19.94 millionN/A0.00Short Interest ↓
News Coverage
This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.